Germanium Organic/Ge-132 / propagermanium (organogermanium) / ROS Cancer Research Results

Ge-132, Germanium Organic/Ge-132 / propagermanium (organogermanium): Click to Expand ⟱
Features: organic

Organic Germanium

Common names include germanium-132 (Ge-132) and germanium sesquioxide(listed seperately).
Small amounts of germanium are found in certain minerals and plant products, including:
argyrodite
germanite
garlic
ginseng
aloe
comfrey

"At present, germanium is widely recognized as a vital trace element, which is particularly essential for the normal functioning of the immune system and plays a significant role in cancer prevention"(note this statement is not universally accepted)

Organogermanium / Ge-132 / propagermanium — comprises synthetic carbon-containing germanium compounds based on carboxyethylgermanium or oxygermylpropionic-acid structures. Ge-132, formally poly-trans-[(2-carboxyethyl)germasesquioxane] and commonly called carboxyethylgermanium sesquioxide or bis(2-carboxyethylgermanium) sesquioxide, hydrolyzes in aqueous environments to 3-(trihydroxygermyl)propanoic acid. Propagermanium is the pharmaceutical 3-oxygermylpropionic acid polymer and is marketed in Japan as Serocion for selected HBe-antigen-positive chronic hepatitis B patients. Ge-132 and propagermanium are closely related organogermanium preparations but should not be assumed to be chemically, pharmaceutically or clinically interchangeable with every product marketed as “organic germanium.” Purified organogermanium has substantially lower experimental renal toxicity than germanium dioxide, but germanium is not an essential nutrient and product contamination with inorganic germanium remains an important safety concern.

Primary mechanisms (ranked):

  1. Inhibition of CCL2-mediated CCR2 signaling by propagermanium, reducing monocyte chemotaxis, tumor-associated myeloid-cell recruitment and formation of prometastatic niches.
  2. Immune activation through increased IL-1, IL-2 and interferon production, with stimulation of cytotoxic T lymphocytes, natural killer cells, macrophages and antibody-mediated antigen clearance.
  3. Macrophage- and T-lymphocyte-dependent antitumor activity in murine Ge-132 models, occurring predominantly through host immune modulation rather than direct tumor-cell cytotoxicity.
  4. Antioxidant and cytoprotective modulation in normal cells, including reduced ROS, inflammatory signaling and oxidative-stress-induced apoptosis.
  5. Reversible binding of the Ge-132 hydrolysate to physiological cis-diol compounds and sequestration of sulfide species, potentially contributing to metabolic, inflammatory and analgesic effects.

Bioavailability / PK relevance: Ge-132 and propagermanium produce measurable systemic germanium exposure after oral administration but have preparation-specific pharmacokinetics. After very large single Ge-132 doses in healthy volunteers, peak plasma germanium occurred within approximately 0.75–2 hours and the terminal half-life was approximately 5–6 hours, while less than 11% of the administered germanium was recovered in urine within 24 hours. Pharmaceutical propagermanium at a 15 mg single dose reached peak plasma concentration near 3 hours with a half-life near 2.4 hours; its structural unit was reportedly not metabolized, and urinary and fecal elimination were substantial. Because renal clearance contributes materially, exposure may increase with severe renal impairment.

In-vitro vs systemic exposure relevance: Ge-132 is hydrolyzed in water and biological fluids, so experiments using Ge-132 or its hydrolysate must be interpreted according to the actual chemical species and concentration present. Antioxidant, sulfide-binding and cis-diol-complex experiments commonly use micromolar-to-millimolar concentrations that may exceed exposure from ordinary supplement use. The CCL2-related oncology rationale is not primarily based on direct tumor-cell cytotoxicity; it depends on modulation of monocytes, macrophages, myeloid-derived suppressor cells and the tumor microenvironment.

Clinical evidence status: Preclinical for anticancer efficacy, with limited Phase I human oncology evidence. A perioperative dose-escalation study in 12 patients with primary breast cancer found propagermanium doses of 30–90 mg/day feasible without dose-limiting toxicity, but it was not designed to demonstrate reduced recurrence, metastasis or survival benefit. A single historical remission report involving oral germanium sesquioxide cannot establish causality. Propagermanium has prescription-drug status in Japan for improvement of viral markers in selected HBe-antigen-positive chronic hepatitis B, not for cancer. No validated randomized cancer trial supports Ge-132 or propagermanium as an anticancer treatment or adjunct.

Organogermanium Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CCL2 and CCR2 signaling ↓ prometastatic signaling indirectly
↓ myeloid-supported progression		 ↓ CCL2-induced monocyte chemotaxis R Suppression of inflammatory cell recruitment Propagermanium appears to act through CCR2-associated glycosylphosphatidylinositol-anchored proteins rather than conventional competitive occupancy of the CCL2-binding site.
2 Tumor-associated macrophages and myeloid suppressor cells ↓ premetastatic niche formation
↓ metastasis (model-dependent)		 ↓ monocyte and macrophage tissue recruitment G Tumor-microenvironment modulation The antimetastatic rationale is supported mainly by animal models. The small breast-cancer Phase I trial demonstrated feasibility and biomarker effects, not clinical anticancer efficacy.
3 Interferon and cytokine induction ↓ tumor survival indirectly (model-dependent) ↑ IFN-α
↑ IFN-β
↑ IFN-γ
↑ IL-1
↑ IL-2		 G Innate and adaptive immune activation Most mechanistic evidence derives from murine Ge-132 or propagermanium studies and the Japanese propagermanium pharmacology dossier.
4 Cytotoxic T cells and NK cells ↓ tumor or infected-cell survival indirectly ↑ cytotoxic T-cell induction
↑ NK-cell activity		 G Cell-mediated cytotoxicity Propagermanium is clinically classified as an immune modulator rather than a directly acting antiviral or cytotoxic cancer drug.
5 Macrophage antitumor function ↓ tumor growth (model-dependent) ↑ macrophage activation
↑ phagocytic activity		 G Host-mediated tumor suppression Murine Ge-132 antitumor effects were substantially dependent on macrophages and T lymphocytes. Direct activity against human cancer cells is not established.
6 Oxidative stress and apoptosis ↔ mixed or insufficient evidence ↓ ROS
↓ oxidative apoptosis
↓ cellular injury		 R Antioxidant cytoprotection Purified Ge-132 or repagermanium protected normal cultured cells against oxidative injury. This should not be interpreted as tumor-selective ROS elevation or cancer-cell killing.
7 Inflammatory cytokines ↓ tumor-promoting inflammation (context-dependent) ↓ IL-6
↓ inflammatory injury		 G Anti-inflammatory modulation Anti-inflammatory effects may coexist with increased immune-stimulatory cytokines because the direction depends on cell type, stimulus, disease state and organogermanium preparation.
8 Physiological cis-diol complex formation ↔ uncertain ↔ adrenaline
↔ ATP
↔ nucleoside interactions		 R Reversible molecular complex formation The Ge-132 hydrolysate forms complexes with selected cis-diol-containing molecules. The clinical significance and relevance to cancer remain uncertain.
9 Sulfide and Cav3.2 signaling ↔ uncertain ↓ sulfide-dependent Cav3.2 activation
↓ pain signaling		 R Experimental analgesic activity THGP can sequester sulfide species and suppress Cav3.2-dependent pain in experimental systems. This is a secondary non-cancer mechanism.
10 Clinical Translation Constraint ↔ efficacy unproven ↑ exposure with renal impairment
↑ hepatic risk in susceptible patients		 G Restricted therapeutic applicability Cancer data are predominantly preclinical. Commercial product purity is variable, inorganic germanium contamination can negate the apparent safety advantage, and pharmaceutical propagermanium carries disease-specific hepatic warnings.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy 
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination




Item ROS↑ NRF2 Condition Mechanism Class Remarks 



ROS">Piperlongumine
+++ ↓ [D][T] ROS-dominant






ROS">Shikonin
+++↓/±[D][T]ROS-dominant






ROS">Vitamin K3 (menadione)
+++↓[D]ROS-dominant






ROS">Copper (ionic / nano)
+++↓[Fe][F]ROS-dominant






ROS">Sodium Selenite
+++↓[D]ROS-dominant






ROS">Juglone
+++↓[D]ROS-dominant






ROS">Auranofin
+++↓[D]ROS-dominant






ROS">Photodynamic Therapy (PDT)
+++0[L][O₂]ROS-dominant






ROS">Radiotherapy / Radiation
+++0[O₂]ROS-dominant






ROS">Doxorubicin
+++↓[D]ROS-dominant






ROS">Cisplatin
++↓[D][T]ROS-dominant






ROS">Salinomycin
++↓[D][T]ROS-dominant






ROS">Artemisinin / DHA
++↓[Fe][T]ROS-dominant






ROS">Sulfasalazine
++↓[C][T]ROS-dominant






ROS">FMD / fasting
++↓[M][C][O₂]ROS-dominant






ROS">Vitamin C (pharmacologic)
++↓[Fe][D]ROS-dominant






ROS">Silver nanoparticles
++±[F][D]ROS-dominant






ROS">Gambogic acid
++↓[D][T]ROS-dominant






ROS">Parthenolide
++↓[D][T]ROS-dominant






ROS">Plumbagin
++↓[D]ROS-dominant






ROS">Allicin
++↓[D]ROS-dominant






ROS">Ashwagandha (Withaferin A)
++↓[D][T]ROS-dominant






ROS">Berberine
++↓[D][M]ROS-dominant






ROS">PEITC
++↓[D][C]ROS-dominant






ROS">Methionine restriction
+↓[M][C][T]ROS-secondary






ROS">DCA
+±[M][T]ROS-secondary






ROS">Capsaicin
+±[D][T]ROS-secondary






ROS">Galloflavin
+0[D]ROS-secondary






ROS">Piperine
+±[D][F]ROS-secondary






ROS">Propyl gallate
+↓[D]ROS-secondary






ROS">Scoulerine
+?[D][T]ROS-secondary






ROS">Thymoquinone
±±[D][T]Dual redox






ROS">Emodin
±±[D][T]Dual redox






ROS">Alpha-lipoic acid (ALA)
±↑[D][M]NRF2-dominant






ROS">Curcumin
±↑/↓[D][F]NRF2-dominant






ROS">EGCG
±↑/↓[D][O₂]NRF2-dominant






ROS">Quercetin
±↑/↓[D][Fe]NRF2-dominant






ROS">Resveratrol
±↑[D][M]NRF2-dominant






ROS">Sulforaphane
±↑↑[D]NRF2-dominant






ROS">Lycopene
0↑—Antioxidant






ROS">Rosmarinic acid
0↑—Antioxidant






ROS">Citrate
00—Neutral


Scientific Papers found: Click to Expand⟱
7124- Ge-132,    Physiological Activity of Trace Element Germanium including Anticancer Properties
- Review, Var, NA
*toxicity↓, Risk↓, Dose↝, AntiCan↑, AntiTum↑, Inflam↓, OXPHOS↝, *toxicity↓, *toxicity↓, other↑, eff↑, *Bacteria↓, *AntiFungal↑, eff↑, eff↑, ROS↑, eff↑, toxicity↝, *H2O2↓, *ROS↓, Warburg↓,
7131- Ge-132,    Antioxidant Activity of Ge-132, a Synthetic Organic Germanium, on Cultured Mammalian Cells
- in-vitro, Nor, CHO K1
*ROS↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

OXPHOS↝, 1,   ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Warburg↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   Risk↓, 1,   toxicity↝, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

H2O2↓, 1,   ROS↓, 2,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Bacteria↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:429  Target#:275  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page